10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology
- None.
- None.
The introduction of GEM-X by 10x Genomics represents a significant advancement in the field of single cell and spatial biology. The technological enhancements such as increased sensitivity, ability to scale and cost reduction per cell are poised to strengthen the company's competitive position in the market. These improvements are likely to attract a broader range of researchers due to lowered barriers to entry, potentially leading to increased sales volume.
Moreover, the focus on enhanced data quality and maximum sample recovery addresses critical pain points in the industry, which could translate into higher customer satisfaction and retention rates. The strategic move to accept preorders aligns with an anticipated demand surge, allowing the company to manage its supply chain effectively and gauge early market interest.
However, it's essential to monitor the adoption rate post-launch, as it will provide a more accurate measure of market reception and the technology's impact on the company's financial performance. The long-term success of GEM-X will also depend on the continuous development of the promised robust roadmap, which could drive sustained revenue growth if executed effectively.
The announcement of GEM-X technology is a forward-looking event that may have a positive impact on 10x Genomics' stock performance. The preorder availability and the expected shipment within the current quarter could be a sign of strong revenue growth in the short term. Investors typically respond well to product innovations that promise to expand a company's market share and reduce costs, potentially leading to margin improvements.
However, investors will be keen on understanding the capital expenditures required for the development and production of GEM-X, as well as the sales and marketing expenses associated with its launch. The balance between these costs and the incremental revenue generated will be critical in evaluating the financial impact of this new technology.
Additionally, the dependence of GEM-X on the Chromium X Series instruments may limit its market to existing customers or those willing to invest in the entire system, which could influence the speed of revenue realization. Investors should look for updates on sales figures and market penetration in subsequent earnings calls and reports to assess the financial trajectory influenced by GEM-X.
The launch of GEM-X technology by 10x Genomics marks a noteworthy evolution in single cell genomics, a field that is critical for precision medicine and complex biological research. The technological advancements in microfluidics and reagent optimization are expected to enhance the capabilities of researchers in deciphering cellular heterogeneity and immune profiling.
The ability to detect up to two times more genes and the reduction in multiplet rate are particularly important for studies requiring high-resolution data, such as cancer research and immunology. These features could lead to a higher rate of discovery and more detailed insights into disease mechanisms, potentially accelerating the pace of scientific breakthroughs.
It is also significant that 10x Genomics is positioning GEM-X as a platform with a robust roadmap, indicating a long-term commitment to innovation in this space. The company's strategy to drive broad adoption through economic incentives aligns with the industry's need for cost-effective, high-throughput technologies. The impact on the biotechnology sector will likely be measured by the rate at which GEM-X enables new research and its influence on the standardization of single cell analysis methodologies.
GEM-X, the next generation of the company's leading single cell technology architecture, enables higher performance at larger scale and lower cost
Pre-orders now open for first two Chromium products powered by GEM-X; expected to ship in Q1
"With GEM-X, we are advancing our leadership in single cell analysis, raising the bar on performance and setting a new standard for the field," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer of 10x Genomics. "This is a game-changing technology that will help drive better, faster and more cost effective single cell research and enable more academic and translational researchers to routinely rely on these tools to help resolve biology's complexity."
The company is now accepting preorders for the first two product launches powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3'v4 and Chromium Single Cell Immune Profiling 5'v3. These assays are expected to begin shipping this quarter.
The new GEM-X technology offers significant performance advantages, including:
- Substantially increased sensitivity: Detect up to two times more genes compared to on-market Chromium assays to gain a more comprehensive view of cellular heterogeneity
- Built to scale: Two-fold increase in cells captured per channel
- More cost effective: More than two-fold reduction in cost per cell
- Enhanced data quality: Two-fold reduction in multiplet rate enabling high quality data at scale
- Maximum sample recovery: Recovery of up to
80% of cells, improving capture efficiency and making it ideal for samples typically yielding few cells, such as tissue biopsies or previously flow sorted cells - Improved assay robustness: Redesigned microfluidics and optimized reagents for faster and more efficient cell partitioning
"This is just the beginning for GEM-X and for single cell analysis," added Schnall-Levin. "We have a robust GEM-X roadmap ahead, including a comprehensive menu of high performance assays and applications with the economics to drive broad adoption and large scale."
GEM-X is exclusively available for use on Chromium X Series instruments.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s ("10x Genomics") product launches, performance, configuration, costs, capabilities, adoption and pipeline. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-expands-leadership-in-single-cell-analysis-with-launch-of-gem-x-technology-302056515.html
SOURCE 10x Genomics, Inc
FAQ
What is the ticker symbol for 10x Genomics, Inc.?
What products are now available for pre-orders powered by the GEM-X technology architecture?
When are the pre-ordered products expected to ship?
What are the advantages of GEM-X technology?
What instruments is GEM-X exclusively available for use on?
